Targeted immune cells: A fresh approach to treating atherosclerosis

Conflict of interest

Xianbin Kong is an Editorial Board Member of this journal. All authors declare no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

References

[1] Nie H, Yan C, Zhou W, Li TS. Analysis of immune and inflammation characteristics of atherosclerosis from different sample sources. Oxid Med Cell Longev. 2022; 2022: 5491038. doi: 10.1155/2022/5491038

[2] Soehnlein O, Libby P. Targeting inflammation in atherosclerosis - from experimental insights to the clinic. Nat Rev Drug Discov. 2021; 20(8): 589-610. doi: 10.1038/s41573-021-00198-1

[3] Nilsson J, Hansson GK, Shah PK. Immunomodulation of atherosclerosis: Implications for vaccine development. Arterioscler Thromb Vasc Biol. 2005; 25(1): 18-28. doi: 10.1161/01.ATV.0000149142.42590.a2

[4] Depuydt MAC, Schaftenaar FH, Prange KHM, et al. Single-cell T cell receptor sequencing of paired human atherosclerotic plaques and blood reveals autoimmune-like features of expanded effector T cells. Nat Cardiovasc Res. 2023; 2(2): 112-125. doi: 10.1038/s44161-022-00208-4

[5] Wang Y, Li W, Zhao T, et al. Interleukin-17-producing CD4⁺ t cells promote inflammatory response and foster disease progression in hyperlipidemic patients and atherosclerotic mice. Front Cardiovasc Med. 2021; 8: 667768. doi: 10.3389/fcvm.2021.667768

[6] Yang G, Qiu Y. Effects of amlodipine combined with atorvastatin on Th17/Treg imbalance and vascular microcirculation in hypertensive patients with atherosclerosis: A double-blind, single-center randomized controlled trial. Medicine (Baltimore). 2023; 102(6): e32384. doi: 10.1097/MD.0000000000032384

[7] Slutter B, Ley K. Editorial: Adaptive immunity in atherosclerosis. Front Immunol. 2024; 15: 1440283. doi: 10.3389/fimmu.2024.1440283

[8] Khambhati J, Engels M, Allard-Ratick M, Sandesara PB, Quyyumi AA, Sperling L. Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities. Atherosclerosis. 2018; 276: 1-9. doi: 10.1016/j.atherosclerosis.2018.07.007

[9] Mushenkova NV, Bezsonov EE, Orekhova VA, Popkova TV, Starodubova AV, Orekhov AN. Recognition of oxidized lipids by macrophages and its role in atherosclerosis development. Biomedicines. 2021; 9(8): 915. doi: 10.3390/biomedicines9080915

[10] Fang F, Ni Y, Yu H, et al. Inflammatory endothelium-targeted and cathepsin responsive nanoparticles are effective against atherosclerosis. Theranostics. 2022; 12(9): 4200-4220. doi: 10.7150/thno.70896

[11] Distasio N, Dierick F, Ebrahimian T, Tabrizian M, Lehoux S. Design and development of branched poly(ss-aminoester) nanoparticles for interleukin-10 gene delivery in a mouse model of atherosclerosis. Acta Biomater. 2022; 143: 356-371. doi: 10.1016/j.actbio.2022.02.043

[12] Banka AL, Guevara MV, Brannon ER, et al. Cargo-free particles divert neutrophil-platelet aggregates to reduce thromboinflammation. Nat Commun. 2023; 14(1): 2462. doi: 10.1038/s41467-023-37990-z

[13] Engelen SE, Robinson AJB, Zurke Y, Monaco C. Therapeutic strategies targeting inflammation and immunity in atherosclerosis: How to proceed?. Nat Rev Cardiol. 2022; 19(8): 522-542. doi: 10.1038/s41569-021-00668-4

[14] May LT, Bartolo BA, Harrison DG, et al. Translating atherosclerosis research from bench to bedside: Navigating the barriers for effective preclinical drug discovery. Clin Sci (Lond). 2022; 136(23): 1731-1758. doi: 10.1042/CS20210862

[15] Shakeri A, Wang Y, Zhao Y, et al. Engineering organ-on-a-chip systems for vascular diseases. Arterioscler Thromb Vasc Biol. 2023; 43(12): 2241-2255. doi: 10.1161/ATVBAHA.123.318233

[16] Winkels H, Wolf D. Heterogeneity of t cells in atherosclerosis defined by single-cell RNA-sequencing and cytometry by time of flight. Arterioscler Thromb Vasc Biol. 2021; 41(2): 549-563. doi: 10.1161/ATVBAHA.120.312137

[17] Klumper N, Saal J, Berner F, et al. C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer. J Immunother Cancer. 2022; 10(3): e004024. doi: 10.1136/jitc-2021-004024

[18] Witkowski M, Weeks TL, Hazen SL. Gut microbiota and cardiovascular disease. Circ Res. 2020; 127(4): 553-570. doi: 10.1161/CIRCRESAHA.120.316242

[19] Gong B, Guo Y, Li Y, et al. Immune checkpoint inhibitors in cancer: The increased risk of atherosclerotic cardiovascular disease events and progression of coronary artery calcium. BMC Med. 2024; 22(1): 44. doi: 10.1186/s12916-024-03261-x

[20] Ait-Oufella H, Lavillegrand JR, Tedgui A. Regulatory t cell-enhancing therapies to treat atherosclerosis. Cells. 2021; 10(4): 723. doi: 10.3390/cells10040723

[21] Wang L, Gao B, Wu M, Yuan W, Liang P, Huang J. Profiles of immune cell infiltration in carotid artery atherosclerosis based on gene expression data. Front Immunol. 2021; 12: 599512. doi: 10.3389/fimmu.2021.599512